Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04433572 · ClinicalTrials.gov registry record · Phase 3
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
A Phase 3 study of Peripheral Artery Disease and Critical Limb Ischemia, sponsored by Mercator MedSystems.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 2
- Study locations
NCT04433572 is a Phase 3 study of Peripheral Artery Disease and Critical Limb Ischemia that is actively recruiting participants, run by Mercator MedSystems. The registered enrollment target is 250 participants, above the 122-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (105% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT04433572, a Phase 3 study of Peripheral Artery Disease and Critical Limb Ischemia, is actively recruiting participants, sponsored by Mercator MedSystems.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 2
- Study locations
Study Summary
A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major amputation, clinically driven target lesion revascularization, and clinically relevant target lesion occlusion after revascularization of lesions below the knee in patients with symptomatic Rutherford 3-5 peripheral artery disease. The primary safety endpoint will be gathered at 1-month post-index procedure. The primary efficacy endpoint will be gathered at 6 months post-index procedure. Participants will be followed for up to 5 years post-index procedure.
Conditions Studied
Interventions
- DRUG Temsirolimus
- DRUG Saline placebo
Study Locations (2)
Louisiana
- Cardiovascular Institute of the South - Houma
Texas
- UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2032-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04433572
The ClinicalTrials.gov registry entry for NCT04433572 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 122-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (105% higher). The listed sponsor is Mercator MedSystems, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Peripheral Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Temsirolimus is the first listed.
NCT04433572 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Louisiana, Texas.
Frequently Asked Questions
What is clinical trial NCT04433572 about?
NCT04433572 is a clinical study titled "Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee". A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major amputation, clinically driven target lesion revascularization, and clinically relevant target lesion occlusion after rev...
What is the current status of trial NCT04433572?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-07-30. Estimated completion is 2032-08-01.
What conditions does trial NCT04433572 study?
This clinical trial studies the following conditions: Peripheral Artery Disease, Critical Limb Ischemia.
What interventions are being tested in trial NCT04433572?
The interventions under investigation include: Temsirolimus (DRUG), Saline placebo (DRUG).
Who is sponsoring clinical trial NCT04433572?
This trial is sponsored by Mercator MedSystems, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04433572 being conducted?
This trial has 2 study locations across Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
The COCOA-PAD II Trial
RECRUITING · Phase 3
-
Improve PAD PERformance With METformin
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
COMPLETED · Phase 3
-
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
COMPLETED · Phase 3
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.